Antiemetics for Oncology

By October 31, 2026: (1) Billing team must update EMR/billing system to reflect revised coverage criteria for antiemetic medications, specifically adding 'less than 7 hours of sleep the night before chemotherapy' as a qualifying risk factor for NK1 RA, 5HT3 RA, and combination products used with moderate-emetic-risk agents. (2) Update or create prior authorization templates to include the new sleep deprivation risk factor. (3) Modify clinical documentation templates to capture sleep status the night before chemotherapy. (4) Oncology providers and nursing staff must be notified that oral antiemetics (e.g., tablets) are now covered under this policy ONLY when administered in the infusion center prior to chemotherapy—not for take-home self-administration; adjust counseling and dispensing practices accordingly. (5) Audit recent claims (last 30 days) for antiemetic denials that may now be approvable under expanded criteria and consider resubmission. (6) Train billing staff on distinction between preferred products (NK1 RA: Cinvanti, Emend, Focinvez, Varubi; 5HT3 RA: Aloxi, Kytril, Posfrea, Sustol, Zofran; combination: Akynzeo) and non-preferred alternatives; non-preferred products now require documentation of trial failure or intolerance to preferred agents. Failure to implement these changes will result in claim denials for otherwise-eligible patients and may require appeal of previously denied claims.